Daan Gene Co., Ltd. (SHE:002030)

China · Delayed Price · Currency is CNY

5.75

+0.11 (1.95%)

Sep 30, 2026, 3:04 PM CST

Market Cap	8.07B -8.6%
Revenue (ttm)	746.91M -5.6%
Net Income	-682.60M
EPS	-0.50
Shares Out	1.40B
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	23,684,518
Open	5.64
Previous Close	5.64
Day's Range	5.56 - 5.80
52-Week Range	4.80 - 8.20
Beta	0.45
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 26, 2026

About Daan Gene

Daan Gene Co., Ltd., together with its subsidiaries, researches and develops, manufactures, and sells clinical test reagents, instruments, and supporting consumables in China. It operates through two segments, Biological Products and Related Business and Financial Business. The company offers PCR testing kits, including hepatitis virus, human papillomavirus (HPV), sexually transmitted infections sexually transmitted infections, human immunodeficiency virus, blood screening, respiratory infections, digestive pathogens, public health, coronavirus... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 1988

Employees 1,506

Stock Exchange Shenzhen Stock Exchange

Ticker Symbol 002030

Full Company Profile

Financial Performance

In 2025, Daan Gene's revenue was 757.66 million, a decrease of -11.18% compared to the previous year's 853.02 million. Losses were -744.38 million, -19.54% less than in 2024.

Financial Statements